A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study

Overview of attention for article published in Lancet Oncology, November 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

news: 1 news outlet
twitter: 27 X users

facebook: 3 Facebook pages

Readers on

mendeley: 145 Mendeley

So far, Altmetric has seen 29 X posts from 27 X users, with an upper bound of 189,222 followers.

A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study. https://t.co/wLBxriq9XR H/T @NCBI #radonc #PubMed https://t.co/TN9vh8BvES

RT @StayCurrentApp: Making sense of #NRSTS staging: @COGorg risk based strategy for #Pediatric #Sarcoma 5⃣Factors: size, POG grade, mets,…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 25 additional X posts.